Recent noteworthy reports on diffuse large B-cell lymphoma (DLBCL) include positive survival results with an antibody-drug ...

A doctor and survivor share what you need to know. Named after the 19th-century scientist who first described abnormal masses ...

Acalabrutinib combined with lenalidomide and rituximab shows promising results as a frontline treatment for follicular lymphoma, achieving high response rates.

Authors of a recent editorial appearing in the Journal of the National Cancer Institute say opening clinical trials in ...

Thanks to efforts from doctors, researchers, health care providers and nonprofits such as Blood Cancer United, certain types of blood cancers are not the terminal diagnoses that these were decades ago ...

Rochester, N.Y. — A trailblazing new study suggests a new way to effectively treat certain types of cancer. Research conducted at the Wilmot Cancer Institute shows immunotherapy to be highly effective ...

During a live event, Ann F. Mohrbacher, MD, discussed outcomes from the latest follow-up of the ZUMA-7 and TRANSFORM trials.

Outcomes in patients (pts) with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) treated with systemic therapy from real world experience (ORCHID) study. This is an ASCO Meeting ...

VANCOUVER, British Columbia — In patients with refractory or relapsed aggressive lymphoma, immunoradiation combined with high-dose chemotherapy is associated with better progression-free and overall ...

Jacob Miller of Merrimack and a team of 26 other residents, known as Miller’s Crew, will represent the town in the 37th annual Jimmy Fund Walk on Oct. 5. “Every step you take gives patients like me ...

NSHL is the most common type of Hodgkin’s lymphoma and mostly affects children and young adults. It’s highly curable with prompt treatment, so recognizing the symptoms can be important. Hodgkin’s ...